Stoked Bio is pioneering efforts to combat two significant medical challenges: antimicrobial resistance and glioblastoma. In a recent webinar hosted by GEN, co-founder Jon Stokes, PhD, and CEO Jeff Skinner, MBA, outlined how their innovative platform utilizes a “biology-first” approach combined with artificial intelligence to enhance drug discovery.
During the session, the panelists emphasized the urgent need to address these persistent issues, as both resistance mechanisms in pathogens and tumor evolution in cancers like glioblastoma continue to thwart existing treatments. Through their unique Mosaic platform, Stoked Bio aims to identify new therapeutics for these difficult-to-treat conditions by integrating biological insights with advanced computational models.
The Mosaic platform employs phenotypic screening alongside proprietary datasets and generative AI, creating a robust framework for discovering drugs that effectively target pathogens and cancer cells. This method not only accelerates the process of drug discovery but also aims to lower costs and reduce early-stage development failures.
Key points discussed in the webinar included the advantages of a biology-first strategy in identifying novel compounds for challenging conditions, including drug-resistant infections and glioblastoma. The panel also highlighted how Stoked Bio utilizes CDD Vault to translate academic research into scalable biotech solutions.
Stokes, who has a background in microbiology and artificial intelligence, has made significant contributions to antibiotic discovery, particularly through machine learning applications. Skinner, with extensive experience in the pharmaceutical and biotech sectors, focuses on fostering strategic partnerships to drive the development of next-generation therapeutics.
The webinar concluded with a live question and answer session, allowing attendees to engage directly with the experts and delve deeper into the innovative approaches being employed by Stoked Bio.
As the fight against antimicrobial resistance and glioblastoma continues, platforms like Mosaic represent a hopeful avenue for the development of effective new treatments.
